Phase I trial of KB 003 in volunteers.

Trial Profile

Phase I trial of KB 003 in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Lenzilumab (Primary)
  • Indications Obstructive airway disorders; Rheumatic disorders
  • Focus Adverse reactions
  • Sponsors Humanigen; KaloBios Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
    • 05 May 2008 New trial record.
    • 29 Apr 2008 Subject dosing has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top